dromlakhani Assess for hypopituitarism and replace hormone deficits
STEP 1 — Gather Information
Collect clinical symptoms of pituitary deficiency (fatigue, weight change, cold/heat intolerance, hypotension, hypoglycemia, loss of libido, menstrual disturbances, erectile dysfunction) and baseline laboratory tests: morning cortisol or ACTH stimulation test, TSH with free T4, LH/FSH with estradiol (women) or testosterone (men), prolactin, and review prior IGF‑1 and GH levels. Document any history of pituitary surgery, radiation, or tumor size.
Action: Proceed to step 2 to evaluate for hypopituitarism based on symptoms and labs.
STEP 2 — Rule In / Rule Out
If any suggestive symptom or any abnormal baseline pituitary hormone (low cortisol, low TSH with low/normal free T4, low LH/FSH/sex steroids, or inappropriately low prolactin) is present → rule in possible hypopituitarism.
If no symptoms and all baseline pituitary hormones are normal → rule out clinically significant hypopituitarism at this time.
Action: If ruled in, proceed to step 3 to classify deficient axes; if ruled out, continue routine acromegaly monitoring and reassess if symptoms develop.
STEP 3 — Classify or Stratify
Classify deficiency by axis: central adrenal (low cortisol with inadequate ACTH response), central hypothyroidism (low/normal TSH with low free T4), central gonadal (low LH/FSH with low sex steroids), and note GH axis (IGF‑1 low despite GH excess is atypical; GH replacement generally contraindicated in active acromegaly). Stratify severity as mild (asymptomatic, lab‑only), moderate (symptomatic but stable), or severe (symptomatic with hemodynamic instability or myxedema).
Action: Document deficient axes and their severity, then proceed to step 4 for replacement decisions.
STEP 4 — Decide
Initiate physiologic hormone replacement for each deficient axis: glucocorticoid (hydrocortisone) for adrenal insufficiency, levothyroxine for central hypothyroidism, sex steroid (testosterone/estrogen±progestin) for gonadal deficiency; monitor for overtreatment and adjust doses to maintain target levels (e.g., morning cortisol 5‑25 µg/dL, TSH within reference, sex steroids in age‑appropriate range). Avoid GH replacement unless pituitary surgery/radiation has cured acromegaly and IGF‑1 remains low after oncologic control.
Action: Start replacement, schedule follow‑up clinical assessment and labs in 6‑8 weeks, then every 6‑12 months or sooner if symptoms change.
Clinical Guardrails / Mimics / Pitfalls
Do not initiate glucocorticoids without confirming adrenal insufficiency due to risk of adrenal suppression; avoid over‑replacement of thyroid hormone which can exacerbate cardiomyopathy or atrial fibrillation or bone loss; recognize that central hypothyroidism may present with normal or low TSH, so free T4 must be checked; prolactin elevation from stalk effect often does not require dopamine agonist unless symptomatic; GH replacement is contraindicated in active acromegaly as it may stimulate tumor growth; stress‑dose glucocorticoids are needed during illness or surgery for adrenal‑insufficient patients.
Concrete Clinical Example
A 48‑year‑old woman with acromegaly undergoes transsphenoidal surgery; postoperative IGF‑1 normalizes. Six months later she reports fatigue, weight gain, and amenorrhea. Labs show morning cortisol 4 µg/dL (low), ACTH 5 pg/mL (low/normal), TSH 0.8 µIU/mL (low‑normal) with free T4 0.6 ng/dL (low), LH 1.2 IU/L, FSH 2.0 IU/L, estradiol <15 pg/mL. Diagnosis: central adrenal insufficiency, central hypothyroidism, and gonadal deficiency. She is started on hydrocortisone 15 mg AM/5 mg PM, levothyroxine 75 µg daily, and transdermal estradiol 50 µg twice weekly with cyclic progesterone. Symptoms improve at 8‑week follow‑up; labs are now within target ranges. She continues routine acromegaly surveillance with annual pituitary hormone review.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700